CompanyGraph
GenFleet Therapeutics (Shanghai) Inc.
2595 · HKEX · China
Price data from its Y3L listing on XDUS, quoted in EUR
genfleet.comFinancials as of FY2025
At a glance
- Depends onUpstream position: supplies 6 industries, depends on 3
- ScaleRevenue is $19.33M, lower than 95% of all stocks globally
- FinancialsAltman Z-Score 10.71: safe zone
- Interpretations1 currently firing — 1
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
Financials view
Market Capitalization
10.61BHKD1.35B · vs all stocks (USD)
Revenue (TTM)
151.60MCNY19.33M · vs all stocks (USD)
52-Week Change
46.15%vs all stocks
Market Capitalization
10.61BHKD1.35B · vs all stocks (USD)
Enterprise Value
21.72BHKD2.77B · vs all stocks (USD)
Forward P/E
-44.77xvs Biotechnology peers
Price to Sales (TTM)
91.96xvs Biotechnology peers
Price to Book (MRQ)
9.77xvs Biotechnology peers
Enterprise to Revenue
143.26xvs Biotechnology peers
Enterprise to EBITDA
-67.98xvs Biotechnology peers
Operating Margin
-463.40%vs Biotechnology peers
Return on Assets (TTM)
-12.49%vs Biotechnology peers
Return on Equity (TTM)
-98.89%vs Biotechnology peers
Revenue (TTM)
151.60MCNY19.33M · vs all stocks (USD)
Revenue per Share (TTM)
0.4400CNYUpdated Aug 19, 2026Quarterly Revenue Growth
-60.30%vs Biotechnology peers
Gross Profit (TTM)
97.36MCNY12.41M · vs all stocks (USD)
EBITDA (TTM)
-319.49MCNY-40.73M · vs all stocks (USD)
Net Income (TTM)
-2.09BCNY-266.25M · vs all stocks (USD)
Operating Cash Flow (TTM)
-157.93MCNY-20.13M · vs all stocks (USD)
Levered Free Cash Flow (TTM)
-2.58BCNY-328.57M · vs all stocks (USD)
Trailing Annual Dividend Rate
0.00HKDUpdated Aug 19, 2026Trailing Annual Dividend Yield
0.00%vs all stocks
Payout Ratio
0.00%vs Biotechnology peers
Revenue
130.27MCNYFY2025 · Dec 31, 2025Cost of Goods Sold
46.61MCNYFY2025 · Dec 31, 2025Gross Profit
83.66MCNYFY2025 · Dec 31, 2025Operating Income
-276.55MCNY-41.01M · vs all stocks (USD)
Pre-tax Income
-1.79BCNYFY2025 · Dec 31, 2025Income Tax Expense
152.00KCNYFY2025 · Dec 31, 2025Net Income
-1.79BCNYFY2025 · Dec 31, 2025EBIT
-1.79BCNYFY2025 · Dec 31, 2025EBITDA (Income Statement)
-1.78BCNYFY2025 · Dec 31, 2025Research & Development
282.26MCNYFY2025 · Dec 31, 2025Selling, General & Administrative
81.38MCNYFY2025 · Dec 31, 2025Non-operating Interest Income
31.18MCNYFY2025 · Dec 31, 2025Non-operating Interest Expense
6.39MCNYFY2025 · Dec 31, 2025EPS (Basic)
-6.07CNYFY2025 · Dec 31, 2025EPS (Diluted)
-6.07CNYFY2025 · Dec 31, 2025Basic Shares Outstanding
295.81MSharesFY2025 · Dec 31, 2025Diluted Shares Outstanding
295.81MSharesFY2025 · Dec 31, 2025Preferred Stock Dividends
0.00CNYFY2025 · Dec 31, 2025Operating Cash Flow
-1.74BCNYFY2025 · Dec 31, 2025Free Cash Flow
-1.74BCNYFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
1.20BCNYFY2025 · Dec 31, 2025Starting Profit (CF Statement)
-1.79BCNYFY2025 · Dec 31, 2025Stock-based Compensation
26.27MCNYFY2025 · Dec 31, 2025Other Non-cash Items
-24.79MCNYFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
93.23MCNYFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
-35.91MCNYFY2025 · Dec 31, 2025Capital Expenditures
-40.00KCNYFY2025 · Dec 31, 2025Net Intangibles (CF)
-5.00KCNYFY2025 · Dec 31, 2025Purchase of Investments
-1.03BCNYFY2025 · Dec 31, 2025Sale of Investments
203.32MCNYFY2025 · Dec 31, 2025Net Investing Cash Flow
-825.48MCNYFY2025 · Dec 31, 2025Long-term Debt Payments
-56.13MCNYFY2025 · Dec 31, 2025Net Short-term Debt Issuance
32.77MCNYFY2025 · Dec 31, 2025Net Financing Cash Flow
1.80BCNYFY2025 · Dec 31, 2025Shares Outstanding
370.37MSharesUpdated Aug 19, 2026% Held by Insiders
19.21%vs all stocks
% Held by Institutions
16.05%vs all stocks
Total Cash (MRQ)
2.41BCNY307.82M · vs all stocks (USD)
Total Cash per Share (MRQ)
3.14CNYUpdated Aug 19, 2026Total Debt (MRQ)
117.45MCNY14.97M · vs all stocks (USD)
Total Debt to Equity (MRQ)
0.0556xvs Biotechnology peers
Current Ratio (MRQ)
5.85xvs Biotechnology peers
Book Value per Share (MRQ)
3.19CNYUpdated Aug 19, 2026Total Assets
2.20BCNY325.61M · vs all stocks (USD)
Total Current Assets
2.16BCNYFY2025 · Dec 31, 2025Total Liabilities
381.01MCNYFY2025 · Dec 31, 2025Total Non-current Assets
34.11MCNYFY2025 · Dec 31, 2025Total Non-current Liabilities
11.52MCNYFY2025 · Dec 31, 2025Total Current Liabilities
369.49MCNYFY2025 · Dec 31, 2025Cash
367.92MCNYFY2025 · Dec 31, 2025Cash Equivalents
829.52MCNYFY2025 · Dec 31, 2025Cash & Cash Equivalents
1.20BCNYFY2025 · Dec 31, 2025Other Short-term Investments
877.25MCNYFY2025 · Dec 31, 2025Accounts Receivable
15.92MCNYFY2025 · Dec 31, 2025Inventory
17.34MCNYFY2025 · Dec 31, 2025Accounts Payable
24.13MCNYFY2025 · Dec 31, 2025Short-term Debt
89.40MCNYFY2025 · Dec 31, 2025Long-term Debt
11.52MCNYFY2025 · Dec 31, 2025Common Stock (Book)
37.04MCNYFY2025 · Dec 31, 2025Retained Earnings
-3.10BCNYFY2025 · Dec 31, 2025Total Shareholders' Equity
1.81BCNY269.10M · vs all stocks (USD)
52-Week Low
19.60HKDUpdated Aug 19, 202652-Week High
52.90HKDUpdated Aug 19, 202652-Week Change
46.15%vs all stocks
50-Day MA
31.19HKDUpdated Aug 19, 2026200-Day MA
31.60HKDUpdated Aug 19, 2026Avg 10-Day Volume
1.30MSharesUpdated Aug 19, 2026Avg 30-Day Volume
2.29MSharesUpdated Aug 19, 2026Diluted EPS (TTM)
-7.06CNYUpdated Aug 19, 20261 interpretation currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsIs this company financially stable?
Multi-Year Debt Decrease With Cash Near Total Debt And Equity
Long-term debt down in each of four years, and cash now covers most or all of what is left.
Reads
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Financial Health
Altman Z-Score 10.71: safe zoneNotable
Altman Z-Score: 10.71
Supply Chain
Upstream position: supplies 6 industries, depends on 3Notable
Outgoing: 6.00Incoming: 3.00
Scale
Revenue is $19.33M, lower than 95% of all stocks globallySignificant
Revenue (USD): 19,327,755.426Global P5: 30,274,777.221
Levered free cash flow is -$328.57M, lower than 95% of all stocks globallySignificant
Levered free cash flow (USD): -328,565,766.71Global P5: -219,013,500
Market cap is $1.35B, above the global median of $1.15BNotable
Market cap (USD): 1,353,269,077.534Global Median: 1,146,734,693.424
Companies that share the same coordination system — how they create, deliver, or capture value.
Phibro Animal Health Corporation
Tier 1ProductionApproval-Gated PipelineRule
EL.En. S.p.A.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Novavax Inc.
Tier 1ProductionApproval-Gated PipelineRule
Changzhou Qianhong Biopharma Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Chongqing Taiji Industry Group Co. Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Aurisco Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineFlowRule
Absci Corporation
Tier 1ProductionApproval-Gated PipelineRuleSenseMaking
Alphatec Holdings Inc.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Qingdao Haier Biomedical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Companies that share active interpretations — structural patterns currently present in both stocks.
Nanjing Xinjiekou Department Store Co. Ltd.
1 interpretationMulti-Year Debt Decrease With Cash Near Total Debt And Equity
Halo Microelectronics Co., Ltd.
1 interpretationMulti-Year Debt Decrease With Cash Near Total Debt And Equity
Olaplex Holdings, Inc.
1 interpretationMulti-Year Debt Decrease With Cash Near Total Debt And Equity